Question? Reach Us: (949) 990-4490
Bremelanotide

Ideal for

  • Individuals with sexual desire concerns
  • Appropriate patients seeking libido support
  • Those eligible for medically supervised treatment

Libido

Bremelanotide (PT-141)

Bremelanotide (PT-141)

Bremelanotide (PT-141) is a melanocortin receptor agonist that may be prescribed as part of our medically supervised sexual health program. It may be considered for appropriate patients experiencing certain sexual desire concerns. Treatment is available only after evaluation by one of our licensed healthcare providers, who will determine whether it is medically appropriate based on individual health history and treatment needs.

  • Supports Sexual Desire – May help improve sexual desire in appropriate patients with certain diagnosed sexual desire disorders.
  • Supports Sexual Interest – Acts on melanocortin pathways involved in sexual desire and arousal.
  • As-Needed Treatment – May be prescribed for use as needed rather than as a daily medication, depending on the individualized treatment plan.
  • Non-Hormonal Mechanism – Works through melanocortin receptors rather than by directly providing or replacing sex hormones.
  • Bremelanotide (PT-141) is a melanocortin receptor agonist used in prescription treatment for certain sexual desire concerns.
  • This compounded formulation is prepared and dispensed by a qualified pharmacy pursuant to an individualized prescription.
  • Bremelanotide is administered by subcutaneous injection. Use only as prescribed by our licensed healthcare providers. Follow the individualized dose, timing, frequency, administration, and storage instructions provided by our medical team and the dispensing pharmacy. Do not change your prescribed dose or frequency without consulting our medical team.

Q: What is Bremelanotide (PT-141)?
A: Bremelanotide is a melanocortin receptor agonist available by prescription. An FDA-approved bremelanotide product is indicated for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Our licensed healthcare providers will determine whether treatment is medically appropriate based on an individual evaluation.

Q: How is Bremelanotide administered?
A: Bremelanotide is administered by subcutaneous injection. Patients should follow the individualized dosing, timing, and administration instructions provided by our medical team and dispensing pharmacy.

Q: When should Bremelanotide be used?
A: Bremelanotide should be used only according to the timing and frequency prescribed by our licensed healthcare providers. Instructions may vary depending on the prescribed formulation and individual treatment plan.

Q: What results can I expect?
A: Individual responses vary, and specific results cannot be guaranteed. Our medical team will discuss treatment goals and may monitor your response to determine whether continued treatment is appropriate.

Q: Is Bremelanotide safe?
A: Bremelanotide may cause side effects and is not appropriate for everyone. Potential side effects can include nausea, flushing, headache, vomiting, injection-site reactions, and temporary increases in blood pressure. Our licensed healthcare providers will review relevant health history, medications, potential risks, and contraindications before determining whether treatment is appropriate.

Q: Who should not use Bremelanotide?
A: Bremelanotide may not be appropriate for patients with certain medical conditions, including uncontrolled high blood pressure or known cardiovascular disease. Our licensed healthcare providers will evaluate relevant health information before prescribing treatment.

Q: Why is a medical evaluation required?
A: Our medical evaluation allows a licensed healthcare provider to review symptoms, health history, current medications, potential contraindications, and treatment options before determining whether Bremelanotide is medically appropriate.

Q: Is this compounded formulation FDA-approved?
A: No. Compounded medications are not FDA-approved. When clinically appropriate, our licensed healthcare providers may prescribe a compounded formulation for an individual patient. The dispensing pharmacy provides formulation-specific information and instructions.

  1. Food and Drug Administration. (2019). Vyleesi (bremelanotide injection) prescribing information. Retrieved from FDA.
  2. Edinoff, A. N., et al. (2022). Bremelanotide for treatment of female hypoactive sexual desire disorder. Cureus, 14(1). Retrieved from PubMed.
  3. Mayer, D., et al. (2020). New drug approved for treating hypoactive sexual desire disorder in premenopausal women. Journal of Midwifery & Women’s Health. Retrieved from PubMed.
  4. Clayton, A. H., et al. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women. Drugs in Context. Retrieved from PubMed.

A medical intake form is required prior to receiving a prescription. A licensed healthcare provider will review it and determine your eligibility for this product. Click the Get Started button to fill up your intake form.​

Want to Know More About Our Products?

Eternelle - Health and Wellness

Orange County, CA
(Virtual Services Nationwide)

(949) 990-4490

hello@eternellehealth.com

Book Your Consultation

Oops! We could not locate your form.

Eternelle - Health and Wellness

Orange County, CA
(Virtual Services Nationwide)

(949) 990-4490

hello@eternellehealth.com

Start your wellness journey